New cytogenetic abnormalities are frequent in AML and MDS relapsing after allogeneic hematopoietic cell transplantation (HCT).

被引：0
|
作者：
Pollyea, Daniel A.
Artz, Andrew S.
Stock, Wendy
Daugherty, Christopher
Godley, Lucy
Odenike, Olatoyosi M.
Rich, Elizabeth
Smith, Sonali M.
Zimmerman, Todd
Zhang, Yanming
Huo, Dezheng
Larson, Richard
Van Besien, Koen
机构：
[1] Cook Cty Hosp, Chicago, IL USA
[2] Univ Chicago Hosp, Chicago, IL 60637 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3675.3675
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3675
引用
收藏
页码：1050A / 1050A
页数：1
相关论文
共 50 条
  • [31] The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor-risk cytogenetic abnormalities
    Hassanein, Mona
    El Fakih, Riad
    Rasheed, Walid
    Ahmed, Syed
    Shaheen, Marwan
    Chaudhri, Naeem
    Alsharif, Fahad
    Ahmed, Shad
    Hanbali, Amr
    Alshaibani, Alfadel
    Alfraih, Feras
    Alhayli, Saud
    Elhassan, Tusneem
    Alahmari, Ali
    Alzahrani, Hazzaa
    Almohareb, Fahad
    Aljurf, Mahmoud
    Hashmi, Shahrukh
    EJHAEM, 2021, 2 (02): : 249 - 256
  • [32] THE NOVEL 5-GROUP CYTOGENETIC RISK CLASSIFICATION OF MYELO-DYSPLASTIC SYNDROME (MDS), MONOSOMAL KARYOTYPE, AND OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
    Gerds, A.
    Gooley, T.
    Scott, B. L.
    Appelbaum, F. R.
    Deeg, H. F.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S212 - S212
  • [33] Spleen Status and Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
    Akpek, Gorgun
    Pasquini, Marcelo C.
    Agovi, Manza-A
    Logan, Brent
    Cooke, Kenneth R.
    Maziarz, Richard T.
    Gupta, Vikas
    Lazarus, Hillard M.
    Hale, Gregory A.
    Marks, David I.
    Maharaj, Dipnarine
    Popat, Uday
    Carabasi, Matthew
    Bornhaeuser, Martin
    Bolwell, Brian J.
    Ringden, Olle
    Ballen, Karen K.
    Rizzo, J. Douglas
    McCarthy, Philip L.
    Ho, Vincent T.
    BLOOD, 2010, 116 (21) : 1432 - 1433
  • [34] Impact of comorbidity on the outcome of allogeneic hematopoietic stem cell transplantation in AML/MDS patients.
    Shahjahan, M
    Alamo, J
    Delima, M
    Khouri, I
    Gajewski, J
    Andersson, BS
    Champlin, RE
    Giralt, S
    BLOOD, 2003, 102 (11) : 708A - 708A
  • [35] Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS
    R M Sobecks
    L Rybicki
    M Yurch
    M Kalaycio
    R Dean
    S Andresen
    B Pohlman
    H Duong
    B Bolwell
    E Copelan
    Bone Marrow Transplantation, 2012, 47 : 633 - 638
  • [36] Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS
    Sobecks, R. M.
    Rybicki, L.
    Yurch, M.
    Kalaycio, M.
    Dean, R.
    Andresen, S.
    Pohlman, B.
    Duong, H.
    Bolwell, B.
    Copelan, E.
    BONE MARROW TRANSPLANTATION, 2012, 47 (05) : 633 - 638
  • [37] Hematopoietic cell transplantation (HCT) in MDS patients of older age
    Niederwieser, Christian
    Kroeger, Nicolaus
    LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 570 - 584
  • [38] Efficacy of Low-Dose Decitabine in the Early Relapse of AML/MDS after Allogeneic Hematopoietic Stem Cell Transplantation
    Xu Guo-Fa
    Chen Ting
    Liu Huanfeng
    Lin Shijia
    Lei Gao
    Cheng Zhang
    Yao Liu
    Xi Zhang
    Zeng, Defu
    Kong Peiyan
    BLOOD, 2018, 132
  • [39] Efficacy of Lenalidomide and Bortezomib for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing after Allogeneic Stem Cell Transplantation
    Brunner, Andrew M.
    Blonquist, Traci M.
    McMasters, Malgorzata
    Hobbs, Gabriela S.
    McAfee, Steven L.
    Rosenblatt, Jacalyn
    Amrein, Philip C.
    Connolly, Christine
    Ramos, Aura Y.
    Mikami, Kaleb
    Logan, Emma
    Dey, Bimalangshu R.
    Spitzer, Thomas
    Avigan, David E.
    Chen, Yi-Bin
    Ballen, Karen K.
    El-Jawahri, Areej
    Fathi, Amir T.
    BLOOD, 2018, 132
  • [40] Prognostic Effect of ASXL1 Mutations in Patients with MDS and Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation
    Koenecke, Christian
    Thol, Felicitas
    Loeffeld, Patrick
    Buchholz, Stefanie
    Stadler, Michael
    Goehring, Gudrun
    Dammann, Elke
    Kleine, Moritz
    Brauns, Wiebke
    Hallensleben, Michael
    Schmidtke, Joerg
    Schlegelberger, Brigitte
    Krauter, Juergen
    Ganser, Arnold
    Heuser, Michael
    BLOOD, 2011, 118 (21) : 744 - 745
12345